MDS05: Advancing therapies in Myelodysplasia: . A multi-domain platform trial for patients with myelodysplasia investigating new treatments – The Master Protocol

ACTRN 12622000410752

Brief Summary

Traditionally, combination therapy has not proven to be effective in Myelodysplasia (MDS) given the increased toxicity of drugs used in combination with standard therapies. The aim of this master platform trial is to test a range of novel treatments aimed at targeting MDS to find safe and effective drug combinations.

Intervention/Treatment

• Varies

Inclusion Criteria

1. Provision of written informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment..
2. Provision of written informed consent to the ALLG NBCR.
3. Age 18+ (Age 16-17 permitted if consent for minor PICF approved by the authorising HREC).
4. A diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of MDS or AML with less than 30% blasts.